The BEACON Study (Breast Cancer Outcomes With NKTR-102)
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The study is designed as an open-label, randomized, parallel, two arm, multicenter,
international Phase 3 study in patients with recurrent or metastatic breast cancer previously
treated with cytotoxic chemotherapy regimens.
The primary study objective is to compare overall survival of patients who receive NKTR-102
given once every 21 days to patients who receive treatment of Physician's Choice selected
from a list of seven single-agent intravenous therapies.